Tracer library / [177Lu]Lu-DTPA-NY003

[177Lu]Lu-DTPA-NY003

Also written as [Lu-177]Lu-DTPA-NY003

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Breast cancer Preclinical only, no clinical indication yet Other radioligand therapy

What it is

Compound class: Anti-TROP-2 antibody conjugated with DTPA chelator (radiolabeled antibody)
Target / mechanism: Targets Trophoblast cell-surface antigen-2 (TROP-2), a transmembrane glycoprotein overexpressed in TNBC PMID 38194043
Clinical application: Radioimmunotherapy (RIT) of TROP-2 positive triple-negative breast cancer in preclinical xenograft model PMID 38194043
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
SmartModule X	custom manifold	SPE	96% not corrected	>99%	DTPA-NY003	38194043 2024 EJNMMI Radiopharm Chem A self-designed radiolabelling module (SmartModule X) was employed for radiochemical synthesis. - The non-decay-corrected radiochemical yields of [89Zr]Zr-DFO-NY003 and [177Lu]Lu-DTPA-NY003 were 56% and 96%, respectively.

Need this precursor?We can point you to suppliers for [177Lu]Lu-DTPA-NY003, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38194043. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38194043: 'Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model.'.